Additionally, BMS will gain access to Tempus’ Lens Platform, an AI-first, agentic platform for oncology drug development built on one of the world’s largest, real-world multimodal datasets. Connected to state-of-the-art GPU infrastructure, this dedicated environment will allow BMS researchers to train and execute advanced AI models using de-identified data to surface breakthroughs faster and increase the probability of technical success when developing candidate therapies at scale.
This agreement expands upon the long-standing strategic relationship between Tempus and BMS, which includes applying AI and multimodal real-world data to optimize clinical trial design across high-priority oncology programs and neuroscience initiatives.
Also, Pathos AI, a clinical-stage AI and technology company advancing its own therapeutic pipeline, today announced multi-year strategic collaborations with Bristol Myers Squibb (NYSE:BMY, "BMS"))) and Tempus AI, Inc. (NASDAQ:TEM, "Tempus"))) to build a specialized, curated dataset and agentic AI capabilities for Alzheimer’s disease and other neurological conditions. BMS also leads Pathos’s Series E financing and gains access to Pathos Foundry across its broader R&D portfolio.
Tempus will apply the infrastructure and expertise it has built in oncology to create a comprehensive, de-identified, longitudinal dataset from hundreds of thousands of patients with neurological conditions, designed to track outcomes over time and accelerate biological insight. Pathos will license the data from Tempus under a five-year, $55 million agreement.
Pathos will apply its AI platform, Pathos Foundry, to interrogate the dataset at scale, generate and test hypotheses on disease biology, and inform the design of more targeted, adaptive clinical trials. Pathos built and validated this approach in oncology, where it guides decisions across the company’s clinical-stage pipeline, including adapting trial design in real time to improve its projected probability of success.
The collaboration builds on BMS's broader strategy to combine advanced AI with deep scientific and disease-area expertise to make faster, higher-confidence decisions that drive innovation for patients. BMS is helping expand the application of Pathos Foundry into neuroscience, securing three-year exclusive rights in an area where the company brings deep research, clinical-development expertise and a growing portfolio of programs in Alzheimer’s disease and other neurological conditions. Through multi-year access to the platform across its broader portfolio and the specialized dataset developed through the definitive agreements, BMS aims to generate deeper insights into disease progression, identify patients most likely to benefit from potential therapies and design more precise clinical trials.